

ZELIRA THERAPEUTICS

# A Global Biopharmaceutical Company Developing and Marketing Clinically Validated Cannabinoid-Based Medicines

AGM 13 JANUARY 2022



ASX: ZLD  
OTCQB:ZLDAF  
[zeliratx.com](http://zeliratx.com)



# Disclaimer & Important Notice

## Disclaimer

This presentation has been prepared by Zelira Therapeutics Ltd ACN 103 782 378 ("Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the availability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.



## Future Matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.



# Your Board

## GLOBAL



### Dr. Oludare Odumosu **CEO & Managing Director**

- Post-clinical development of Iroko Pharmaceutical's Zorvolex® Tivorbex® and Vivlodex® through FDA approvals and successful US market commercialization.
- Founding COO of Ilera Healthcare. Ilera Healthcare was acquired by TerrAscend (TER.CN) for \$225 Mid 2019. Founding CSO/EVP of Ilera Therapeutics.

## USA



### Osagie Imasogie **Chairman**

- Over 30 years in the field of law, finance, business management, healthcare and the pharmaceutical industry.
- Founder and VP for Glaxo Smith Kline ("GSK") Ventures.
- Co-founder and the Senior Managing Partner of PIPV Capital, a Private Equity Firm focused on the Life Sciences vertical.
- Chairman and Founder of Ilera Healthcare, Ilera Therapeutics, iCeutica Inc., Churchill Pharma, Ception Therapeutics Inc. and Trigenesis Therapeutics Inc.



### Lisa Gray **Director**

- Served as COO for Glaxo Smith Kline ("GSK") Ventures.
- Co-Founder and Vice Chair of Ilera Healthcare, and lead on the sale of this business to TerrAscend.
- Vice Chair for Ilera Holistic Healthcare and Ilera Therapeutics.
- Co-Founder and Managing Partner of PIPV Capital.

## AUSTRALIA



### Harry Karelis **Vice Chairman**

- Founding Director/Shareholder of numerous ASX-listed companies including in the global medicinal cannabis sector.
- +25 years corporate/finance experience, specialising in med-tech private equity investing.
- Co-founder corporate advisory & investment firm Gemelli Group.



### Jason Peterson **Director**

- Founder, Director and Head of Corporate at Stock Broking and Corporate Advisory firm, CPS Capital.
- Founding Director/Shareholder of numerous ASX-listed companies including in the global medicinal cannabis sector.
- +25 years of experience in the financial advisory sector.



## VOTING


# How to Vote


When the poll is open, select the vote icon at the top of the screen


To vote, select either For, Against or Abstain


You will see a vote confirmation

To change or cancel your vote “click here to change your vote” at any time until the poll is closed

  
Broadcast

  
Vote

  
Q&A


  
Documents

### Items of business

2A Re-elect Mr Sam Sample as a Director

FOR	AGAINST	ABSTAIN
-----	---------	---------

2B Re-elect Mrs Jane Citizen as a Director



We have received your vote for  
[Click here to change your vote](#)






## QUESTIONS


# How to ask a Question


To ask a written question select the Q & A icon


Select the topic your question relates to from the drop-down list

Type your question in the text box and press the send button

  
Broadcast

  
Vote

  
Q&A

  
Documents

Your question(s)

You may enter a question using the field below

Select Topic ▼

Questions are limited to 2,000 characters

0 Character(s)

Send

To ask a verbal question follow the instructions below the broadcast window.



# Chairman's Address



# CEO & Managing Director's Address





**Zelira is a global biopharmaceutical company developing, and marketing clinically validated cannabinoid-based medicines.**

It offers investors exposure to a rapidly emerging global industry, with multiple shots on goal - to create significant value.





# Milestones achieved in FY21



**14 July 2020**

Zelira reports Phase 1 dose escalation study in chronic pain patients on long-term opioid treatment meets primary and secondary endpoints



**22 July 2020**

Zelira and Cardiovascular Solutions of Central Mississippi (CVSCM) enter into binding agreement to develop and commercialize products targeting Peripheral Arterial Disease (PAD)



**20 Aug 2020**

HOPE 1 and HOPE 2 launched in Louisiana, USA



**16 Sept 2020**

Zenivol launched in Australia as the world's most clinically validated cannabinoid-based treatment for chronic insomnia



**30 Sept 2020**

Zelira signs real world data agreement for insomnia drug Zenivol with Emyria



**27 Oct 2020**

HOPE 1 and HOPE 2 launched in Australia as TGA adds to Special Access Scheme



**9 Nov 2020**

Zelira partners with Emyria for Autism Observational Trial for HOPE products



**2 Dec 2020**

Zelira partners with SprinJene to launch CBD toothpaste in USA



**14 Dec 2020**

HOPE 1 and HOPE 2 expands distribution with launch in Washington DC, USA



**3 June 2021**

Levin health licensing and management agreement signed to conduct chronic pain treatment clinical trial on retired athletes




**15 June 2021**

Zelira® partners with Health House International via exclusive distribution agreement to launch CBD toothpaste in the United Kingdom



**18 June 2021**

Breakthrough research at Curtin University (Australia) demonstrates significant uptake of CBD into the brain





## Milestones achieved so far in FY22



**12 July 2021**

Zelira US Observational Clinical Pain Trial receives IRB approval



**23 September 2021**

Zelira® Launches RAF FIVE™ Acne Treatment products through its dermatology focussed subsidiary



**20 October 2021**

Zelira® raises US\$5 million from Quincy Street Capital LLC, a US-based family office fund



**3 November 2021**

Zelira® Develops EDCDM technology for making free flow powder from cannabinoid distillate and signs new licensing deal

**Maiden revenues achieved totalling \$663,316 driven by growth in SprinjeneCBD sales, Rx sales, product development agreement, clinical trial management and product licensing fees from Levin Health.**



At a group level, funding values Zelira at

**A\$122.8M**

*US\$5 million raised from US-based family office fund,  
Quincy Street Capital LLC*

**US\$1.5M** A\$2.05M

via an equity investment in Ilera Derm LLC  
(Zelira Dermatology) for a 3% shareholding in that company,  
valuing Zelira Dermatology at US\$50 million.

**US\$3.5M** A\$4.9M

US\$3.5 million (A\$4.79 million) via a  
placement of Zelira fully paid ordinary shares



**Zelda receives a**

**A\$1,292,000**

*Cash refund under the Federal Government's R&D Tax Incentive Scheme*

Funds received will be used to support Zelira's portfolio of products recently launched into global markets and to advance its ongoing clinical development programmes.

The R&D Tax Incentive Scheme is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

The funds will be used to support the growth in recent launched products including Zenivol™ for Insomnia, HOPE™ for Autism and a new CBD-Toothpaste into global markets, and also to advance Zelira's ongoing clinical and product development programs.





## Zelira Patent Portfolio

Zelira's patent portfolio has been granted or under consideration in 26 countries spanning across the globe. There are 41 patents granted and 103 under prosecution across 9 different therapeutic areas

Therapeutic Area	Granted/Allowed	Under Prosecution/Examination
Cancer compositions	8	13
Skin compositions	4	8
Sleep compositions	8	27
Cancer prognosis	18	
Autism compositions		12
Pain compositions	1	16
PTSD/Anxiety composition	1	13
Opioid sparing compositions	1	13
Encapsulation	0	1
<b>Total</b>	<b>41</b>	<b>103</b>



## MULTIPLE REVENUE STREAMS



### Revenue Stream 1

Launch & Learn  
**Rx**

Autism  
Aged disorders  
Insomnia

### Revenue Stream 2

Oral Health  
**OTC**

Toothpaste  
Additional Products, 2022 Launch



### Revenue Stream 3

Dermatology  
**OTC**

Five acne treating  
products launched 2021



### Revenue Stream 4

Clinical Trials  
**Rx**

Insomnia  
Opioid Sparing  
Autism



### Revenue Stream 5















Pharma  
**Rx**

Pain  
GI  
Insomnia





# PIPELINE

Product	Status	Current Markets	Next Steps
Autism   HOPE	Launched 2020	  USA AUS	  GERMANY UK
Insomnia   Zenivol®	Launched 2020	 AUS	   USA GERMANY UK
Oral Care   SprinJene CBD	Launched 2021	  USA UK	 ADDITIONAL PRODUCTS
Dermatology   RAF FIVE™	Launched 2021	 USA	
Targeted Pain	IRB approved observational clinical study Launched 2021	 USA	
Aged Disorder	Launches 2022	 USA	



# Formal Business



## Resolution 1

### Option of Remuneration Report

To consider and, if thought fit, to pass, with or without amendment, the following as an **non-binding resolution**:

*That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as contained in the Company's annual financial report for the financial year ended 30 June 2021.*

FOR	AGAINST	PROXY DISCRETION	ABSTAIN
99,546,110	3,285,199	4,634,196	938,004



## Resolution 2

### **Ratification of Prior Issue of Securities – Quincy Street Capital**

To consider and, if thought fit, to pass, with or without amendment, the following as an **ordinary resolution**:

*That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 79,908,676 Shares and 39,954,338 Options to Quincy Street Capital LLC on the terms and conditions set out in the Explanatory Statement.*

FOR	AGAINST	PROXY DISCRETION	ABSTAIN
<b>172,515,666</b>	<b>2,605,514</b>	<b>4,687,041</b>	<b>1,358,517</b>



### Resolution 3

## Re-Election of Director – Osagie Imasogie

To consider and, if thought fit, to pass, with or without amendment, the following as an **ordinary resolution**:

*That, for the purpose of clause 12.3 of the Constitution, ASX Listing Rule 14.5 and for all other purposes, Osagie Imasogie, a Director, retires, and being eligible, is re-elected as a Director.*

FOR	AGAINST	PROXY DISCRETION	ABSTAIN
253,646,659	1,798,795	4,634,195	983,672





## Resolution 4

### Re-Election of Director – Lisa Gray

To consider and, if thought fit, to pass, with or without amendment, the following as an **ordinary resolution**:

*That, for the purpose of clause 12.3 of the Constitution, ASX Listing Rule 14.5 and for all other purposes, Lisa Gray, a Director, retires, and being eligible, is re-elected as a Director.*

FOR	AGAINST	PROXY DISCRETION	ABSTAIN
251,961,852	3,347,892	4,672,695	1,080,882



## Resolution 5

### Approval Of 10% Placement Capacity

To consider and, if thought fit, to pass, with or without amendment, the following as an **special resolution**:

*That, for the purposes of Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue up to that number of Equity Securities equal to 10% of the issued capital of the Company at the time of issue, calculated in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 and otherwise on the terms and conditions set out in the Explanatory Statement.*

FOR	AGAINST	PROXY DISCRETION	ABSTAIN
251,961,852	3,347,892	3,347,892	1,080,882





# Thank You

Zelira Therapeutics

**Phone** +1-484-630-0650 | **Email** [info@zeliratx.com](mailto:info@zeliratx.com)

[zeliratx.com](http://zeliratx.com)

